dexmedetomidine has been researched along with Liver Cirrhosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, G; Ou, Y; Yang, Y; Yin, F; Zhang, F | 1 |
| Chen, P; Dai, G; Hong, J; Jiang, Y; Li, A; Lin, W; Luo, X; Luo, Y; Ning, X; Peng, S; Qu, C; Wang, H; Xie, P | 1 |
| Harima, Y; Ikeda, K; Kariya, S; Komemushi, A; Kono, Y; Nakatani, M; Sano, A; Suzuki, S; Tanigawa, N; Utsunomiya, K; Yoshida, RY | 1 |
1 trial(s) available for dexmedetomidine and Liver Cirrhosis
| Article | Year |
|---|---|
[Protective effect of ulinastatin combined with dexmedetomidine against hepatic ischemia-reperfusion injury in laparoscopic hepatectomy for liver cancer and cirrhosis: a randomized controlled trial].
Topics: Dexmedetomidine; Hepatectomy; Humans; Interleukin-6; Laparoscopy; Liver Cirrhosis; Liver Neoplasms; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2022 |
2 other study(ies) available for dexmedetomidine and Liver Cirrhosis
| Article | Year |
|---|---|
Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chemokines; Dexmedetomidine; Disease Models, Animal; Disease Progression; Hepatic Stellate Cells; Humans; Interleukin-6; Liver Cirrhosis; Liver Neoplasms; Male; Mice, Inbred C57BL; Neoplasm Metastasis; Receptors, Adrenergic, alpha-2; STAT3 Transcription Factor | 2020 |
[Feasibility and Safety of Dexmedetomidine Sedation in Transarterial Embolization for Hepatocellular Carcinoma with Hepatitis C-Related Cirrhosis].
Topics: Aged; Carcinoma, Hepatocellular; Dexmedetomidine; Embolization, Therapeutic; Feasibility Studies; Female; Hepatitis C; Humans; Hypnotics and Sedatives; Liver Cirrhosis; Liver Neoplasms; Male; Retrospective Studies | 2015 |